MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-019-02596-z

Медицинская библиотека · International journal of hematology · 2019

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.

Sakurai Masatoshi, Kikuchi Taku, Karigane Daiki, Kasahara Hidenori, Matsuki Eri, Hashida Risa, Yamane Yusuke, Abe Ryohei, Koda Yuya, Toyama Takaaki, Kato Jun, Shimizu Takayuki, Yokoyama Yuta, Suzuki Sayo, Nakamura Tomonori, Okamoto Shinichiro, Mori Takehiko

Клиническое исследованиеСтатьяПеревод в очереди

Аннотация

Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. The mean estimated glomerular filtration rate (eGFR) was significantly decreased over 5 years (77 ± 17 to 62 ± 14 ml/min/1.73m², P < 0.001). Higher age and lower eGFR value at initiation of imatinib were significantly associated with development of renal dysfunction by multivariate analyses. Mean hemoglobin levels also significantly decreased over the 5-year period (12.9 ± 1.7 to 12.4 ± 1.3 g/dl, P < 0.01). The rate of decrease in eGFR correlated significantly with hemoglobin levels (correlation coefficient = - 0.249, P < 0.05). Serum erythropoietin (EPO) levels did not increase in 16 patients with both renal dysfunction and anemia (median, 31.9 mIU/ml). In patients who participated in a clinical trial of imatinib discontinuation, mean eGFR (50.0 ± 6.5 to 56.0 ± 10.2 ml/min/1.73m², P < 0.05) and hemoglobin levels (12.0 ± 1.7 to 14.0 ± 1.6 g/dl, P < 0.01) improved significantly at 1 year after discontinuation. These findings suggest that long-term imatinib results in a partially reversible continuous decline in renal function and decreased hemoglobin levels.

Для цитирования: Sakurai Masatoshi, Kikuchi Taku, Karigane Daiki, Kasahara Hidenori, Matsuki Eri, Hashida Risa, Yamane Yusuke, Abe Ryohei, Koda Yuya, Toyama Takaaki, Kato Jun, Shimizu Takayuki, Yokoyama Yuta, Suzuki Sayo, Nakamura Tomonori, Okamoto Shinichiro, Mori Takehiko. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.. International journal of hematology. 2019. DOI: 10.1007/s12185-019-02596-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.